Clinical application in inflammatory demyelinating diseases of central nerve system and neurodegenerative diseases with Neuroinflammmation PET imaging tracer: 18F-DPA-714

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600123338

Enrollment

Unknown

Registered

2026-04-24

Start date

2026-04-27

Completion date

Unknown

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory demyelinating diseases of central nerve system and neurodegenerative diseases

Interventions

RRMS group:[18F]-DPA-714

SPMS group:[18F]-DPA-714

Healthy control group:[18F]-DPA-714

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. MS diagnostic criteria refer to MacDnold diagnostic criteria revised in 2017; MS inclusion criteria: (1) Voluntary subjects, patients, or their legal representatives signed informed consent; (2) Age: 18 ~ 75 years old, including the cut-off value; (3) No MR Contraindications; (4) Voluntary follow-up. 2. With reference to Petersen and other diagnostic criteria for AD patients, the inclusion criteria of AD subjects included: (1) The subjects or their family members complained of obvious memory impairment; (2) Objective memory impairment (such as object memorization, recall, delayed memory, etc.); (3) CDR>=1.0; (4) MMSE 11-23 points; (5) Meet DSM IV and NINCDS-ADRDA criteria for Alzheimer's disease dementia. 3. Healthy control group included: (1) Overall health status; (2) There are no complaints of memory impairment. Cognitive function was normal by the combined screening of MMSE (28-30 points) and MoCA (26-30 points).

Exclusion criteria

Exclusion criteria: 1. History of stroke, HIS > 4; 2. Alcohol addiction; 3. Major mental illnesses: including anxiety disorders, emotional disorders, major psychosis, or drug-induced psychosis; 4. Neurological diseases: including brain tumors, craniocerebral trauma, multiple sclerosis, epilepsy, etc.; 5. Patients with serious medical conditions who are currently using respiratory drugs, cardiovascular drugs, anticonvulsants, or psychoactive substances; 6. People with severe hearing and visual impairment.

Design outcomes

Primary

Measure	Time frame
[18F]-DPA-714;Pharmacokinetic parameters;Regional distribution characteristics in the brain;	—

Secondary

Measure	Time frame
Safety;	—

Countries

China

Contacts

Public ContactJinming Zhang

Department of Nuclear Medicine, The First Medical Center of PLA General Hospital

zhangjm301@163.com+86 138 0121 0291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026